Procept BioRobotics (PRCT) reported a Q1 net loss Thursday of $0.45 per diluted share, narrowing from a loss of $0.51 a year earlier.
Analysts polled by FactSet expected a loss of $0.49.
Revenue for the quarter ended March 31 was $69.2 million, up from $44.5 million a year earlier.
Analysts surveyed by FactSet expected $65.4 million.
For 2025, the surgical robotics company lifted its revenue guidance to $323 million from the previous $320 million. Analysts polled by FactSet expect $322 million.
Shares of the company were up more than 2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.